Review article: clinical pharmacology models of irritable bowel syndrome.
This review describes the basis for development of clinical pharmacology models of irritable bowel syndrome (IBS) and presents a critical analysis of current models. IBS is becoming a more circumscribed diagnosis by improved symptom criteria and this is perceived as helpful progress for the development of suitable models. Concepts about the aetiopathogenesis and pathophysiology of IBS are also evolving. Different models have been established to study specific derangements in motor function, visceral reflexes and conscious perception of gut stimuli. The review also focuses on specific examples of drug evaluation using appropriate and validated models.
Malagelada
J R
JR
Digestive System Research Unit, Hospital General Vall d'Hebron, Autonomous University of Barcelona, Spain.
D003109:Colonic Diseases, Functional / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D005769:Gastrointestinal Motility; D006801:Humans; D006967:Hypersensitivity; D008365:Manometry; D008954:Models, Biological; D009619:Nociceptors